SCHEMBL11027435

SCHEMBL11027435

CN1CCN(c2ccc(Nc3cc(Cc4cc(F)cc(F)c4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 4/20 0.49
▸ SLC2A1 P11166 2/20 0.48
▸ INSR P06213 2/20 0.47
▸ ALK Q9UM73 2/20 0.47
▸ CDK4 P11802 2/20 0.47
▸ CCND1 P24385 1/20 0.47
▸ AURKA O14965 3/20 0.46
▸ NTRK1 P04629 2/20 0.46
▸ IGF1R P08069 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ MAPKAPK2 P49137 1/20 0.46
▸ CDK2 P24941 2/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CCND3 P30281 1/20 0.45
▸ CDK6 Q00534 1/20 0.45
▸ PTK2 Q05397 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ TTK P33981 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11028773 0.92 MAPKAPK2 (0.50) STAT6SLC2A1CDK4CCND1AURKA
SCHEMBL11028029 0.92 CDK4 (0.53) STAT6SLC2A1INSRALKCDK4
SCHEMBL11027886 0.89 SLC2A1 (0.47) STAT6SLC2A1INSRALKCDK4
SCHEMBL11025081 0.88 STAT6 (0.55) STAT6SLC2A1INSRALKCDK4
SCHEMBL11029543 0.87 MAPKAPK2 (0.49) STAT6SLC2A1ALKCDK4CCND1
SCHEMBL11030732 0.87 NTRK1 (0.51) STAT6SLC2A1INSRALKCDK4
SCHEMBL11029685 0.87 CSF1R (0.49) STAT6SLC2A1CDK4CCND1AURKA
SCHEMBL11027579 0.87 SLC2A1 (0.49) STAT6SLC2A1ALKCDK4CCND1
SCHEMBL11025349 0.86 SLC2A1 (0.52) STAT6SLC2A1CDK4CCND1AURKA
SCHEMBL11033167 0.86 BTK (0.48) STAT6SLC2A1INSRALKCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 STAT6 1545/4885SLC2A1 3662/4885INSR 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback